Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Investigational New Drugs
Published in: Investigational New Drugs 2/2007

01-04-2007 | Phase I Studies

Phase I dose escalation clinical trial of phenylbutyrate sodium administered twice daily to patients with advanced solid tumors

Authors: Luis H. Camacho, Jon Olson, William P. Tong, Charles W. Young, David R. Spriggs, Mark G. Malkin

Published in: Investigational New Drugs | Issue 2/2007

Login to get access

Abstract

Background: Phenylbutyrate (PBA), and its metabolite phenylacetate (PAA), induce growth inhibition and cellular differentiation in multiple tumor models. However, despite their potential anti-cancer properties, several pharmacodynamic aspects remain unknown.
Methods: We conducted a dose escalating trial to evaluate twice-daily intravenous PBA infusions for two consecutive weeks (Monday through Friday) every month at five dose levels (60–360 mg/kg/day). Twenty-one patients with the following malignancies were treated: colon carcinoma 4, non-small cell lung carcinoma 4; anaplastic astrocytoma 3, glioblastoma multiforme 3, bladder carcinoma 2, sarcoma 2, and ovarian carcinoma, rectal hemangiopericytoma, and pancreatic carcinoma 1 each.
Results: Conversion of PBA to PAA and phenylacetylglutamine (PAG) was documented without catabolic saturation. Plasma content of PBA ≥1 mM was documented for only 3 h following each dose at the top two dosages. The therapy was well tolerated overall. Common adverse effects included grade 1 nausea/vomiting, fatigue, and lightheadedness. Dose limiting toxicities were short-term memory loss, sedation, confusion, nausea, and vomiting. Two patients with anaplastic astrocytoma and a patient with glioblastoma remained stable without tumor progression for 5, 7, and 4 months respectively.
Conclusions: Administration of PBA in a twice-daily infusion schedule is safe. The maximum tolerated dose is 300 mg/kg/day. Study designs with more convenient treatment schedules and specific molecular correlates may help to further delineate the mechanism of action of this compound. Future studies evaluating PBA's ability to induce histone acetylation and cell differentiation alone or in combination with other anti-neoplastics are recommended.
Literature
1.
Kritchevsky D, Moyer AW, Tesar WC, McCandless RF, Logan JB, Brown RA, et al (1956) The effect of sodium 2-phenylbutyrate in experimental atherosclerosis. Angiology 7(2):156–158PubMed
2.
Brusilow SW (1991) Phenylacetylglutamine may replace urea as a vehicle for waste nitrogen excretion. Pediatr Res 29(2):147–150PubMed
3.
Brusilow SW, Danney M, Waber LJ, Batshaw M, Burton B, Levitsky L, et al (1984) Treatment of episodic hyperammonemia in children with inborn errors of urea synthesis. N Engl J Med 310(25):1630–1634PubMedCrossRef
4.
Samid D, Shack S, Sherman LT (1992) Phenylacetate: a novel nontoxic inducer of tumor cell differentiation. Cancer Res 52(7):1988–1992PubMed
5.
DiGiuseppe JA, Weng LJ, Yu KH, Fu S, Kastan MB, Samid D, et al (1999) Phenylbutyrate-induced G1 arrest and apoptosis in myeloid leukemia cells: structure-function analysis. Leukemia 13(8):1243–1253PubMedCrossRef
6.
Carducci MA, Nelson JB, Chan-Tack KM, Ayyagari SR, Sweatt WH, Campbell PA, et al (1996) Phenylbutyrate induces apoptosis in human prostate cancer and is more potent than phenylacetate. Clin Cancer Res 2(2):379–387PubMed
7.
Samid D, Hudgins WR, Shack S, Liu L, Prasanna P, Myers CE (1997) Phenylacetate and phenylbutyrate as novel, nontoxic differentiation inducers. Adv Exp Med Biol 400A:501–505PubMed
8.
Warrell RP, Jr, He LZ, Richon V, Calleja E, Pandolfi PP (1998) Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J Natl Cancer Inst 90(21):1621–1625PubMedCrossRef
9.
Han S, Wada RK, Sidell N (2001) Differentiation of human neuroblastoma by phenylacetate is mediated by peroxisome proliferator-activated receptor gamma. Cancer Res 61(10):3998–4002PubMed
10.
Lea MA, Sura M, Desbordes C (2004) Inhibition of cell proliferation by potential peroxisome proliferator-activated receptor (PPAR) gamma agonists and antagonists. Anticancer Res 24(5A):2765–2771PubMed
11.
Darmaun D, Welch S, Rini A, Sager BK, Altomare A, Haymond MW (1998) Phenylbutyrate-induced glutamine depletion in humans: effect on leucine metabolism. Am J Physiol 274(5 Pt 1):E801–E807PubMed
12.
Nichols KE, Weinberg JB (1989) Essential amino acid deprivation induces monocytic differentiation of the human HL-60 myeloid leukemia cell line. Blood 73(5):1298–1306PubMed
13.
Zhang X, Wei L, Yang Y, Yu Q (2004) Sodium 4-phenylbutyrate induces apoptosis of human lung carcinoma cells through activating JNK pathway. J Cell Biochem 93(4):819–829PubMedCrossRef
14.
Thibault A, Cooper MR, Figg WD, Venzon DJ, Sartor AO, Tompkins AC, et al (1994) A phase I and pharmacokinetic study of intravenous phenylacetate in patients with cancer. Cancer Res 54(7):1690–1694PubMed
15.
Rudek MA, Zhao M, He P, Hartke C, Gilbert J, Gore SD, et al (2005) Pharmacokinetics of 5-azacitidine administered with phenylbutyrate in patients with refractory solid tumors or hematologic malignancies. J Clin Oncol 23(17):3906–3911PubMedCrossRef
16.
Phuphanich S, Baker SD, Grossman SA, Carson KA, Gilbert MR, Fisher JD, et al (2005) Oral sodium phenylbutyrate in patients with recurrent malignant gliomas: a dose escalation and pharmacologic study. Neuro-oncol 7(2):177–182PubMedCrossRef
17.
Carducci MA, Gilbert J, Bowling MK, Noe D, Eisenberger MA, Sinibaldi V, et al (2001) A Phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule. Clin Cancer Res 7(10):3047–3055PubMed
18.
Gore SD, Weng LJ, Figg WD, Zhai S, Donehower RC, Dover G, et al (2002) Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia. Clin Cancer Res 8(4):963–970PubMed
19.
Gilbert J, Baker SD, Bowling MK, Grochow L, Figg WD, Zabelina Y, et al (2001) A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies. Clin Cancer Res 7(8):2292–2300PubMed
20.
Boudoulas S, Lush RM, McCall NA, Samid D, Reed E, Figg WD (1996) Plasma protein binding of phenylacetate and phenylbutyrate, two novel antineoplastic agents. Ther Drug Monit 18(6):714–720PubMedCrossRef
21.
O'Quigley J, Chevret S (1991) Methods for dose finding studies in cancer clinical trials: a review and results of a Monte Carlo study. Stat Med 10(11):1647–1664PubMed
22.
Piscitelli SC, Thibault A, Figg WD, Tompkins A, Headlee D, Lieberman R, et al (1995) Disposition of phenylbutyrate and its metabolites, phenylacetate and phenylacetylglutamine. J Clin Pharmacol 35(4):368–373PubMed
23.
Thibault A, Figg WD, McCall N, Myers CE, Cooper MR (1994) A simultaneous assay of the differentiating agents phenylacetate and phenylbutyrate, and one of their metabolites, phenylglutamine, by reversed-phase, high performance liquid chromatography. J Liq Chromatogr 17:2895–2900
24.
Thibault A, Samid D, Cooper MR, Figg WD, Tompkins AC, Patronas N, et al (1995) Phase I study of phenylacetate administered twice daily to patients with cancer. Cancer 75(12):2932–2938PubMedCrossRef
25.
Coffey DC, Kutko MC, Glick RD, Swendeman SL, Butler L, Rifkind R, et al (2000) Histone deacetylase inhibitors and retinoic acids inhibit growth of human neuroblastoma in vitro. Med Pediatr Oncol 35(6):577–581PubMedCrossRef
26.
Karasawa Y, Murakami A, Okisaka S (2000) Apoptosis after butyrate-induced differentiation in retinoblastoma cell line Y-79. Jpn J Ophthalmol 44(6):601–609PubMedCrossRef
27.
Pelidis MA, Carducci MA, Simons JW (1998) Cytotoxic effects of sodium phenylbutyrate on human neuroblastoma cell lines. Int J Oncol 12(4):889–893PubMed
28.
Berg S, Serabe B, Aleksic A, Bomgaars L, McGuffey L, Dauser R, et al (2001) Pharmacokinetics and cerebrospinal fluid penetration of phenylacetate and phenylbutyrate in the nonhuman primate. Cancer Chemother Pharmacol 47(5):385–390PubMedCrossRef
29.
Rocchi P, Ferreri AM, Magrini E, Perocco P (1998) Effect of butyrate analogues on proliferation and differentiation in human neuroblastoma cell lines. Anticancer Res 18(2A):1099–1103PubMed
30.
Stockhammer G, Manley GT, Johnson R, Rosenblum MK, Samid D, Lieberman FS (1995) Inhibition of proliferation and induction of differentiation in medulloblastoma- and astrocytoma-derived cell lines with phenylacetate. J Neurosurg 83(4):672–681PubMedCrossRef
31.
Sidell N, Wada R, Han G, Chang B, Shack S, Moore T, et al (1995) Phenylacetate synergizes with retinoic acid in inducing the differentiation of human neuroblastoma cells. Int J Cancer 60(4):507–514PubMed
32.
Ram Z, Samid D, Walbridge S, Oshiro EM, Viola JJ, Tao-Cheng JH, et al (1994) Growth inhibition, tumor maturation, and extended survival in experimental brain tumors in rats treated with phenylacetate. Cancer Res 54(11):2923–2927PubMed
33.
Samid D, Yeh TJ, Shack S (1991) Interferon in combination with antitumourigenic phenyl derivatives: potentiation of IFN alpha activity in-vitro. Br J Haematol 79(Suppl 1):81–83PubMed
34.
Gorospe M, Shack S, Guyton KZ, Samid D, Holbrook NJ (1996) Up-regulation and functional role of p21Waf1/Cip1 during growth arrest of human breast carcinoma MCF-7 cells by phenylacetate. Cell Growth Differ 7(12):1609–1615PubMed
35.
Bar-Ner M, Thibault A, Tsokos M, Magrath IT, Samid D (1999) Phenylbutyrate induces cell differentiation and modulates Epstein-Barr virus gene expression in Burkitt's lymphoma cells. Clin Cancer Res 5(6):1509–1516PubMed
36.
Shack S, Miller A, Liu L, Prasanna P, Thibault A, Samid D (1996) Vulnerability of multidrug-resistant tumor cells to the aromatic fatty acids phenylacetate and phenylbutyrate. Clin Cancer Res 2(5):865–872PubMed
37.
Samid D, Yeh A, Prasanna P (1992) Induction of erythroid differentiation and fetal hemoglobin production in human leukemic cells treated with phenylacetate. Blood 80(6):1576–1581PubMed
38.
Fibach E, Prasanna P, Rodgers GP, Samid D (1993) Enhanced fetal hemoglobin production by phenylacetate and 4-phenylbutyrate in erythroid precursors derived from normal donors and patients with sickle cell anemia and beta-thalassemia. Blood 82(7):2203–2209PubMed
39.
Young CW, Fanucchi MP, Declan Walsh T, Baltzer L, Yaldaei S, Stevens YW, et al (1988) Phase I trial and clinical pharmacological evaluation of hexamethylene bisacetamide administration by ten-day continuous intravenous infusion at twenty-eight-day intervals. Cancer Res 48(24 Pt 1):7304–7309PubMed
40.
Andreeff M, Stone R, Michaeli J, Young CW, Tong WP, Sogoloff H, et al (1992) Hexamethylene bisacetamide in myelodysplastic syndrome and acute myelogenous leukemia: a phase II clinical trial with a differentiation-inducing agent. Blood 80(10):2604–2609PubMed
41.
Maslak P, Chanel S, Camacho LH, Soignet S, Pandolfi PP, Guernah I, et al (2006) Pilot study of combination transcriptional modulation therapy with sodium phenylbutyrate and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic syndrome. Leukemia 20(2):212–217PubMedCrossRef
42.
Camacho LH, Novick S, Tolentino T, Tong WP, Richon V, Warrell RP, Jr (2006) Clinical modulation of gene transcription Via inhibition of histone deacetylase using all-trans retinoic acid plus sodium phenylbutyrate. In: Proceedings of the Am Soc Clin Oncol, 2000, New Orleans, 2000, p 461a
Metadata
Title
Phase I dose escalation clinical trial of phenylbutyrate sodium administered twice daily to patients with advanced solid tumors
Authors
Luis H. Camacho
Jon Olson
William P. Tong
Charles W. Young
David R. Spriggs
Mark G. Malkin
Publication date
01-04-2007
Published in
Investigational New Drugs / Issue 2/2007
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI
https://doi.org/10.1007/s10637-006-9017-4

Other articles of this Issue 2/2007

Investigational New Drugs 2/2007 Go to the issue

Phase II Studies

A Phase II study of SU5416 in patients with advanced or recurrent head and neck cancers

PHASE II STUDIES

A phase II, open label, monotherapy study of liposomal doxorubicin in patients with metastatic malignant melanoma

Preclinical Studies

The 4′-O-benzylated doxorubicin analog WP744 overcomes resistance mediated by P-glycoprotein, multidrug resistance protein and breast cancer resistance protein in cell lines and acute myeloid leukemia cells

Phase II Studies

Rebeccamycin analog for refractory breast cancer: A randomized phase II trial of dosing schedules

Phase I Studies

A phase 1 trial of XK469: Toxicity profile of a selective topoisomerase IIβ inhibitor

Preclinical Studies

The anti-hepatitis drug DDB chemosensitizes multidrug resistant cancer cells in vitro and in vivo by inhibiting P-gp and enhancing apoptosis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits